Solventum Corp (SOLV) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Solventum reported revenue of $8.32B, up 0.9% from $8.25B the year before. Net income was $1.56B (a 18.7% net margin), or $8.88 per diluted share. Gross margin was 53.5% and operating margin was 26.2%. Operating activities generated $369.0M of cash, leaving -$10.0M of free cash flow. At fiscal year end, Solventum held $14.29B in total assets against $9.24B in total liabilities, including $878.0M of cash and equivalents.
Open the full interactive Solventum financials → Quarterly statements, key ratios, valuation history and price charts.
Solventum Key Stats
| Share Price | $86.30 |
|---|---|
| Market Cap | $14.96B |
| P/E Ratio | 9.7 |
| Revenue YoY Growth | +0.9% |
| 52-Week Range | $62.49 – $92.44 |
| Shares Outstanding | 172.7 million (basic, 2026 Q2) |
Solventum Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $8.25B | $8.32B |
| Cost of Goods Sold | $3.17B | $3.40B |
| Gross Profit | $4.59B | $4.45B |
| Operating Income | $1.04B | $2.18B |
| Pre-Tax Income | $605.0M | $1.71B |
| Income Tax | $127.0M | $157.0M |
| Net Income | $479.0M | $1.56B |
| Diluted EPS | $2.76 | $8.88 |
Solventum Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.10B | $2.00B | $2.01B | $2.21B |
| Net Income | $1.27B | $63.0M | $13.0M | $92.0M |
| Diluted EPS | $7.22 | $0.36 | $0.07 | $0.53 |
Solventum Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $762.0M | $878.0M |
| Current Assets | $3.25B | $3.86B |
| Total Assets | $14.46B | $14.29B |
| Current Liabilities | $2.70B | $3.14B |
| Total Long-Term Debt | $8.01B | $5.04B |
| Total Liabilities | $11.50B | $9.24B |
| Shareholders' Equity | $2.96B | $5.05B |
Solventum Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | $1.19B | $369.0M |
| Cash From Investing | -$380.0M | $2.80B |
| Cash From Financing | -$240.0M | -$3.06B |
| Free Cash Flow | $805.0M | -$10.0M |
Figures from Solventum's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Solventum financials page for every line item.
Solventum Company Profile
| Ticker | SOLV |
|---|---|
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Eagan, Minnesota |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001964738 |
Frequently Asked Questions
What was Solventum's revenue in fiscal 2025?
Solventum (SOLV) reported revenue of $8.32B for fiscal 2025.
What was Solventum's net income in fiscal 2025?
Solventum reported net income of $1.56B for fiscal 2025.
What was Solventum's earnings per share (EPS) in fiscal 2025?
Solventum's diluted EPS was $8.88 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Solventum generate in fiscal 2025?
Solventum generated -$10.0M of free cash flow in fiscal 2025.
What was Solventum's revenue last quarter?
In its most recent reported quarter (2026 Q2), Solventum reported revenue of $2.21B.
How much debt does Solventum have?
Solventum reported $5.04B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Solventum are outstanding?
Solventum reported a weighted average of 172.7 million basic shares outstanding in 2026 Q2.
What is Solventum's market cap?
Based on its latest closing price, Solventum (SOLV) has a market capitalization of about $14.96B.
When does Solventum's fiscal year end?
Solventum's fiscal year end, as registered with the SEC, is December 31.
Where is Solventum headquartered?
Solventum lists its business address in Eagan, Minnesota in its SEC filings.